Onur Telli1, Hasmet Sarici2, Musa Ekici3, Berat Cem Ozgur2, Omer Gokhan Doluoglu2, Muzaffer Eroglu2, Tugba Akin Telli4. 1. Ankara University, School of Medicine, Department of Urology Sihhiye 06100 Ankara, Turkey. 2. Ankara Training and Research Hospital, Urology Clinic, Ankara, Turkey. 3. Diskapi Yildirim Bayezit Training and Research Hospital, Urology Clinic, Ankara, Turkey. 4. Hacettepe Univercity, School of Medicine, Department of Internal Medicine, Ankara, Turkey.
Abstract
PURPOSE: To investigate the association between metabolic syndrome and prostate cancer risk in Turkish men. METHODS: We examined data from 220 patients with prostate cancer and 234 men in a control group with benign biopsy results, who had a serum prostate-specific antigen (PSA) level ⩾ 4 ng/ml, or an abnormal digital rectal examination finding and who underwent transrectal ultrasound-guided prostate biopsy at two main training and research hospitals between February 2009 and April 2013. Metabolic syndrome was diagnosed according to The Society of Endocrinology and Metabolism of Turkey metabolic-syndrome criteria. Age, total PSA, waist circumference, body mass index, lipid profiles, fasting blood sugar level, blood pressure level and metabolic syndrome were considered for analysis. RESULTS: A total of 454 patients were enrolled: 85 cases in group 1 (38.6% of 220 prostate cancer cases) and 104 control subjects in group 2 (40.4% of 234 controls) were diagnosed with metabolic syndrome. Higher ages and lower high-density lipoprotein-cholesterol were two parameters that were significant only in the prostate cancer group with metabolic syndrome. There was no significant predictor factor for prostate cancer alone; however, higher triglycerides (odds ratio [OR], 1.286; 95% confidence interval [CI] 1.09-1.82 and 1.142; 95% CI 1.06-1.62) and fasting glucose levels (OR, 1.222; 95% CI 1.08-1.61 and 1.024; 95% CI 1.07-1.82) were significant predictors in both the prostate cancer group and control group. CONCLUSIONS: We found little evidence to support the hypothesis that increased incidence of metabolic syndrome (or its components) contributes to increased incidence of prostate cancer. A larger, prospective, multicentre investigation is mandatory to confirm if there is any relationship between metabolic syndrome and prostate cancer.
PURPOSE: To investigate the association between metabolic syndrome and prostate cancer risk in Turkish men. METHODS: We examined data from 220 patients with prostate cancer and 234 men in a control group with benign biopsy results, who had a serum prostate-specific antigen (PSA) level ⩾ 4 ng/ml, or an abnormal digital rectal examination finding and who underwent transrectal ultrasound-guided prostate biopsy at two main training and research hospitals between February 2009 and April 2013. Metabolic syndrome was diagnosed according to The Society of Endocrinology and Metabolism of Turkey metabolic-syndrome criteria. Age, total PSA, waist circumference, body mass index, lipid profiles, fasting blood sugar level, blood pressure level and metabolic syndrome were considered for analysis. RESULTS: A total of 454 patients were enrolled: 85 cases in group 1 (38.6% of 220 prostate cancer cases) and 104 control subjects in group 2 (40.4% of 234 controls) were diagnosed with metabolic syndrome. Higher ages and lower high-density lipoprotein-cholesterol were two parameters that were significant only in the prostate cancer group with metabolic syndrome. There was no significant predictor factor for prostate cancer alone; however, higher triglycerides (odds ratio [OR], 1.286; 95% confidence interval [CI] 1.09-1.82 and 1.142; 95% CI 1.06-1.62) and fasting glucose levels (OR, 1.222; 95% CI 1.08-1.61 and 1.024; 95% CI 1.07-1.82) were significant predictors in both the prostate cancer group and control group. CONCLUSIONS: We found little evidence to support the hypothesis that increased incidence of metabolic syndrome (or its components) contributes to increased incidence of prostate cancer. A larger, prospective, multicentre investigation is mandatory to confirm if there is any relationship between metabolic syndrome and prostate cancer.
Entities:
Keywords:
metabolic syndrome; prostate biopsy; prostate cancer
Authors: Wildon R Farwell; Leonard W D'Avolio; Richard E Scranton; Elizabeth V Lawler; J Michael Gaziano Journal: J Natl Cancer Inst Date: 2011-04-15 Impact factor: 13.506
Authors: Claudio Pelucchi; Diego Serraino; Eva Negri; Maurizio Montella; Cinzia Dellanoce; Renato Talamini; Carlo La Vecchia Journal: Ann Epidemiol Date: 2011-11 Impact factor: 3.797
Authors: Christel Häggström; Tanja Stocks; David Ulmert; Tone Bjørge; Hanno Ulmer; Göran Hallmans; Jonas Manjer; Anders Engeland; Gabriele Nagel; Martin Almqvist; Randi Selmer; Hans Concin; Steinar Tretli; Håkan Jonsson; Pär Stattin Journal: Cancer Date: 2012-10-22 Impact factor: 6.860
Authors: Gillian Libby; Louise A Donnelly; Peter T Donnan; Dario R Alessi; Andrew D Morris; Josie M M Evans Journal: Diabetes Care Date: 2009-06-29 Impact factor: 19.112
Authors: Richard M Martin; Lars Vatten; David Gunnell; Pål Romundstad; Tom I L Nilsen Journal: Cancer Causes Control Date: 2009-03-11 Impact factor: 2.506
Authors: Juan Morote; Jordi Ropero; Jacques Planas; Juan M Bastarós; Gueisy Delgado; José Placer; Anna Celma; Inés M de Torres; Joan Carles; Jaume Reventós; Andreas Doll Journal: BJU Int Date: 2012-08-09 Impact factor: 5.588
Authors: M Gacci; G I Russo; C De Nunzio; A Sebastianelli; M Salvi; L Vignozzi; A Tubaro; G Morgia; S Serni Journal: Prostate Cancer Prostatic Dis Date: 2017-02-21 Impact factor: 5.554